122 related articles for article (PubMed ID: 38035663)
1. Molecular landmarks of tumor disulfidptosis across cancer types to promote disulfidptosis-target therapy.
Zhao D; Meng Y; Dian Y; Zhou Q; Sun Y; Le J; Zeng F; Chen X; He Y; Deng G
Redox Biol; 2023 Dec; 68():102966. PubMed ID: 38035663
[TBL] [Abstract][Full Text] [Related]
2. Multi-omics analysis of disulfidptosis regulators and therapeutic potential reveals glycogen synthase 1 as a disulfidptosis triggering target for triple-negative breast cancer.
Xie J; Deng X; Xie Y; Zhu H; Liu P; Deng W; Ning L; Tang Y; Sun Y; Tang H; Cai M; Xie X; Zou Y
MedComm (2020); 2024 Mar; 5(3):e502. PubMed ID: 38420162
[TBL] [Abstract][Full Text] [Related]
3. Pan-cancer genetic analysis of disulfidptosis-related gene set.
Liu H; Tang T
Cancer Genet; 2023 Nov; 278-279():91-103. PubMed ID: 37879141
[TBL] [Abstract][Full Text] [Related]
4. Construction of a novel disulfidptosis-related signature for improving outcomes in hepatocellular carcinoma: Observational study.
Chen X; Liang Q; Zhou Y
Medicine (Baltimore); 2023 Oct; 102(40):e35423. PubMed ID: 37800779
[TBL] [Abstract][Full Text] [Related]
5. Identification of disulfidptosis related subtypes, characterization of tumor microenvironment infiltration, and development of DRG prognostic prediction model in RCC, in which
Xu K; Zhang Y; Yan Z; Wang Y; Li Y; Qiu Q; Du Y; Chen Z; Liu X
Front Immunol; 2023; 14():1205250. PubMed ID: 37426643
[TBL] [Abstract][Full Text] [Related]
6. Development and validation of a disulfidptosis-related scoring system to predict clinical outcome and immunotherapy response in acute myeloid leukemia by integrated analysis of single-cell and bulk RNA-sequencing.
Zhong F; Jiang J; Yao FY; Liu J; Shuai X; Wang XL; Huang B; Wang X
Front Pharmacol; 2023; 14():1272701. PubMed ID: 38053840
[No Abstract] [Full Text] [Related]
7. Development and validation of a disulfidptosis and M2 TAM-related classifier for bladder cancer to explore tumor subtypes, immune landscape and drug treatment.
Ren C; Wang Q; Xu Z; Pan Y; Li Y; Liu X
J Cancer Res Clin Oncol; 2023 Nov; 149(17):15805-15818. PubMed ID: 37668798
[TBL] [Abstract][Full Text] [Related]
8. Identification of a disulfidptosis-related genes signature for prognostic implication in lung adenocarcinoma.
Huang J; Zhang J; Zhang F; Lu S; Guo S; Shi R; Zhai Y; Gao Y; Tao X; Jin Z; You L; Wu J
Comput Biol Med; 2023 Oct; 165():107402. PubMed ID: 37657358
[TBL] [Abstract][Full Text] [Related]
9. Disulfidptosis-related signature elucidates the prognostic, immunologic, and therapeutic characteristics in ovarian cancer.
Cong Y; Cai G; Ding C; Zhang H; Chen J; Luo S; Liu J
Front Genet; 2024; 15():1378907. PubMed ID: 38694875
[TBL] [Abstract][Full Text] [Related]
10. Construction and Validation of a Reliable Disulfidptosis-Related LncRNAs Signature of the Subtype, Prognostic, and Immune Landscape in Colon Cancer.
Dong X; Liao P; Liu X; Yang Z; Wang Y; Zhong W; Wang B
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629096
[TBL] [Abstract][Full Text] [Related]
11. Unraveling the role of disulfidptosis-related LncRNAs in colon cancer: a prognostic indicator for immunotherapy response, chemotherapy sensitivity, and insights into cell death mechanisms.
Chi H; Huang J; Yan Y; Jiang C; Zhang S; Chen H; Jiang L; Zhang J; Zhang Q; Yang G; Tian G
Front Mol Biosci; 2023; 10():1254232. PubMed ID: 37916187
[No Abstract] [Full Text] [Related]
12. Identification a unique disulfidptosis classification regarding prognosis and immune landscapes in thyroid carcinoma and providing therapeutic strategies.
Feng Z; Zhao Q; Ding Y; Xu Y; Sun X; Chen Q; Zhang Y; Miao J; Zhu J
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11157-11170. PubMed ID: 37347261
[TBL] [Abstract][Full Text] [Related]
13. Construction of a Novel Disulfidptosis-Related lncRNA Prognostic Signature in Pancreatic Cancer.
Xing F; Qin Y; Xu J; Wang W; Zhang B
Mol Biotechnol; 2023 Sep; ():. PubMed ID: 37733182
[TBL] [Abstract][Full Text] [Related]
14. A novel prognostic signature and immune microenvironment characteristics associated with disulfidptosis in papillary thyroid carcinoma based on single-cell RNA sequencing.
Liao Z; Cheng Y; Zhang H; Jin X; Sun H; Wang Y; Yan J
Front Cell Dev Biol; 2023; 11():1308352. PubMed ID: 38033866
[No Abstract] [Full Text] [Related]
15. A disulfidptosis-related lncRNA prognostic model to predict survival and response to immunotherapy in lung adenocarcinoma.
Zhang HB; Pan JY; Zhu T
Front Pharmacol; 2023; 14():1254119. PubMed ID: 37822882
[No Abstract] [Full Text] [Related]
16. Identification of disulfidptosis-related subgroups and prognostic signatures in lung adenocarcinoma using machine learning and experimental validation.
Wang Y; Xu Y; Liu C; Yuan C; Zhang Y
Front Immunol; 2023; 14():1233260. PubMed ID: 37799714
[TBL] [Abstract][Full Text] [Related]
17. Identification of disulfidptosis-related subtypes and development of a prognosis model based on stacking framework in renal clear cell carcinoma.
Peng K; Wang N; Liu Q; Wang L; Duan X; Xie G; Li J; Ding D
J Cancer Res Clin Oncol; 2023 Nov; 149(15):13793-13810. PubMed ID: 37530800
[TBL] [Abstract][Full Text] [Related]
18. A novel disulfidptosis-associated expression pattern in breast cancer based on machine learning.
Wang Z; Du X; Lian W; Chen J; Hong C; Li L; Chen D
Front Genet; 2023; 14():1193944. PubMed ID: 37456667
[No Abstract] [Full Text] [Related]
19. A bioinformatics approach to identify a disulfidptosis-related gene signature for prognostic implication in colon adenocarcinoma.
Hu G; Yao H; Wei Z; Li L; Yu Z; Li J; Luo X; Guo Z
Sci Rep; 2023 Jul; 13(1):12403. PubMed ID: 37524774
[TBL] [Abstract][Full Text] [Related]
20. The disulfidptosis-related signature predicts prognosis and immune features in glioma patients.
Wang X; Yang J; Yang F; Mu K
Sci Rep; 2023 Oct; 13(1):17988. PubMed ID: 37864127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
